Johnson Pharmacare Limited Establishes New Corporate Office in New Delhi

Johnson Pharmacare Limited , formerly known as Sun and Shine Worldwide Limited, has announced a significant development in its corporate structure. The company's Board of Directors has approved the establishment of a new Corporate Office in New Delhi, marking a strategic move to enhance its operational capabilities.

Key Highlights

New Corporate Office Location: 1002 10th Floor, Vikram Tower, Rajendra Place, New Delhi-110060
Purpose: To support centralized management, administration, and operational functions
Authorized Official: Director Umesh Kumar
Board Meeting Details:
- Date: November 24, 2025
- Time: 5:00 PM to 5:30 PM

Corporate Office Establishment

The Board of Directors of Johnson Pharmacare Limited, in a meeting held on November 24, 2025, approved the setting up of a new Corporate Office. This decision aims to strengthen the company's centralized management and operational capabilities.

Location and Significance

The new Corporate Office will be located at:

Detail	Information
Address	1002 10th Floor, Vikram Tower, Rajendra Place, New Delhi-110060
Purpose	Centralized management, administration, and operational functions

This strategic location in the capital city is expected to enhance the company's administrative efficiency and provide better coordination for its operations.

Authorization and Implementation

The Board has authorized Director Umesh Kumar to oversee the establishment of the new office. His responsibilities include:

Finalizing and executing necessary documents
Overseeing lease agreements and related arrangements
Managing the setup and operationalization of the office

Regulatory Compliance

Johnson Pharmacare Limited has disclosed this development in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company considers this event a material development, highlighting its significance for shareholders and stakeholders.

Company Background

Johnson Pharmacare Limited, previously known as Sun and Shine Worldwide Limited, is registered under CIN: L51100GJ1994PLC022388. The company's registered office is located at Regus, Business Centre, Privilon, East Wing, 2nd Floor, Sarkhej Gandhinagar Highway, Bodakdev, Ahmedabad, Gujarat, India-380054.

This move to establish a new Corporate Office in New Delhi signifies Johnson Pharmacare Limited's commitment to strengthening its operational infrastructure and potentially expanding its presence in the national capital region.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+1.69%	-1.64%	-7.69%	-33.33%	-50.82%	+122.22%

Johnson Pharmacare Limited, a pharmaceutical company, has reported its unaudited financial results for the quarter and half year ended September 30, 2025. The company's Board of Directors approved these results during a meeting held on November 14, 2025.

Financial Performance

The company reported a loss before tax of Rs. 5.68 lakhs for the six-month period ending September 30, 2025. This financial performance indicates ongoing challenges for Johnson Pharmacare in the current fiscal year.

Key Financial Metrics

Based on the available income statement data, here's a breakdown of Johnson Pharmacare's financial performance:

Metric (in Rs. crore)	Q1 FY2026	Q4 FY2025	Change (%)
Revenue	0.00	-0.30	-100.00
EBITDA	-0.10	-0.50	-80.00
Net Profit	-0.10	-0.50	-80.00
EPS (in Rs.)	0.00	-0.01	-100.00

Analysis of Results

Revenue

The company reported zero revenue for the quarter, compared to a negative revenue of Rs. 0.30 crore in the previous quarter. This suggests a complete halt in sales or a potential accounting adjustment.

EBITDA

The Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) showed a loss of Rs. 0.10 crore, an improvement from the Rs. 0.50 crore loss in the previous quarter.

Net Profit

Johnson Pharmacare's net loss narrowed to Rs. 0.10 crore, compared to a loss of Rs. 0.50 crore in the previous quarter, indicating some improvement in overall financial performance.

Earnings Per Share (EPS)

The EPS improved from -0.01 in the previous quarter to 0.00 in the current quarter, aligning with the reduced net loss.

Audit Status

The company's statutory auditors have completed a limited review of these financial results, as stated in the announcement.

Outlook

While the narrowing losses suggest some improvement in Johnson Pharmacare's financial health, the absence of revenue in the current quarter raises concerns about the company's operational status and market positioning. Investors and stakeholders may need to closely monitor future announcements for more clarity on the company's strategic direction and plans to return to profitability.

The pharmaceutical sector often faces challenges related to research and development costs, regulatory approvals, and market competition. Johnson Pharmacare's performance should be viewed in the context of these industry-wide factors.

Investors are advised to conduct their own research and consider seeking professional financial advice before making investment decisions based on these results.